Jardiance Cost in Alaska 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Is the Cash Price of Jardiance in Alaska in 2026?

The retail cash price for Jardiance in Alaska runs approximately $680 per month for a 30-day supply of either the 10 mg or 25 mg tablet. That figure reflects the Boehringer Ingelheim and Eli Lilly manufacturer list price, which Alaska pharmacies pass through with minimal markup because no generic version currently exists to create downward price pressure.

Alaska's geographic spread, small population, and limited pharmacy competition mean cash prices tend to track national list prices closely. Unlike the contiguous 48 states, where regional pharmacy chains sometimes negotiate lower shelf prices, most Alaska pharmacies operate closer to acquisition cost. Residents in Anchorage, Fairbanks, and Juneau will generally see the same $680 baseline at major chains such as Walgreens, Fred Meyer, and Walmart Pharmacy.

Discount aggregators like GoodRx and RxSaver can shave 10 to 20 percent off the cash price at participating stores. That still leaves most patients paying $540 to $620 monthly, which is prohibitive for many Alaskans on fixed incomes. The FDA has not approved a generic empagliflozin formulation as of mid-2025, so no automatic substitution is available at the pharmacy counter [1].

EMPA-REG OUTCOME (N=7,020) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% compared with placebo (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for noninferiority, P=0.04 for superiority) over a median 3.1 years [2]. The cardiovascular death component alone fell by 38% (HR 0.62; 95% CI 0.49 to 0.77; P<0.001). Those results underpin why clinicians consider this drug worth pursuing even at high cost, but they also underscore why finding an affordable access pathway matters for high-risk Alaskan patients.

Does Alaska Medicaid Cover Jardiance?

Alaska Medicaid does not cover Jardiance for most beneficiaries. The Alaska Division of Health Care Services maintains a preferred drug list (PDL) that excludes branded empagliflozin from standard coverage for type 2 diabetes, heart failure, and chronic kidney disease indications as of 2026.

Medicaid programs in many states have added SGLT2 inhibitors to formularies following the cardiovascular and renal outcome data, but Alaska has been slower to update its PDL. Prescribers can submit a prior authorization request arguing medical necessity, but approval rates for Jardiance specifically remain low because the state's preferred alternatives include metformin, sulfonylureas, and certain insulin formulations [3].

Alaska Medicaid beneficiaries who also qualify for Medicare Part D (dual eligibles) may have a different path. Medicare Part D plans are required to cover at least two drugs in each therapeutic class. Some Medicare Advantage plans operating in Alaska place empagliflozin on Tier 3 or Tier 4 with a $60 to $150 copay, which is more manageable than the full cash price. Patients should call their Part D plan's member services or check the Medicare Plan Finder at cms.gov to confirm current tier placement before assuming coverage.

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit is recommended to reduce cardiovascular events" [4]. That guideline language supports prior authorization appeals, even if Alaska Medicaid approval remains difficult to secure.

Is Compounded Empagliflozin Legal in Alaska?

Compounded empagliflozin is legal in Alaska when prepared by a state-licensed 503A compounding pharmacy. Section 503A of the federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare individualized medications for specific patients under a valid prescription, outside the standard FDA drug-approval pathway [5].

Alaska's Board of Pharmacy licenses and inspects 503A compounders operating within the state and recognizes out-of-state 503A pharmacies that ship to Alaskan patients provided those pharmacies hold appropriate licensure in their home state and comply with Alaska dispensing rules. This means a patient in Nome or Kodiak can receive compounded empagliflozin capsules mailed from a licensed facility in the lower 48.

The pricing difference is substantial. Branded Jardiance at $680/month contrasts with compounded empagliflozin at some 503A pharmacies that price the same 10 mg dose at $60 to $120 per month, depending on the compounding overhead and pharmacy's fee structure. That cost reduction can be the deciding factor for uninsured or underinsured Alaskan patients.

A few clinical caveats apply. Compounded formulations are not bioequivalent-tested by the FDA against branded Jardiance. They are not covered by the Boehringer Ingelheim/Lilly savings program. And the pharmacist must use pharmaceutical-grade empagliflozin API, not a bulk drug substance that appears on FDA's "difficult to compound" list. Prescribers should document clinical justification in the chart, and patients should confirm the pharmacy's 503A licensure before filling [5].

The FDA's guidance on 503A compounding, updated in 2024, specifies that empagliflozin does not appear on the FDA's list of drug products that may not be compounded, which means 503A compounders can legally prepare it for individual patients with a valid prescription [5].

Which Insurance Plans Cover Jardiance in Alaska?

Private insurance coverage for Jardiance in Alaska varies significantly by plan. The three main coverage structures Alaskan patients encounter are employer-sponsored commercial plans, individual marketplace plans, and Medicare Part D.

Employer-Sponsored Commercial Plans. Large employers operating in Alaska, including state government, the oil industry, and the military, often use pharmacy benefit managers (PBMs) such as CVS Caremark, Express Scripts, or OptumRx. These PBMs negotiate formulary placement. Jardiance appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) in most commercial formularies. Tier 3 copays typically run $60 to $100 per 30-day fill; Tier 4 copays range from $120 to $200 before the deductible is met.

Individual Marketplace Plans (ACA). Alaska's individual market is served by a small number of insurers. Premera Blue Cross Blue Shield of Alaska is the dominant carrier on the exchange. Premera's 2025 drug formulary places empagliflozin on Tier 3 in most metal-level plans, with copays of $75 to $125 after deductible. Patients should request an exception or step-therapy waiver if a physician has already documented failure of a preferred SGLT2 inhibitor.

Medicare Part D. Standalone Part D plans and Medicare Advantage plans available in Alaska list empagliflozin differently. In 2026, the Medicare $2,000 annual out-of-pocket cap introduced by the Inflation Reduction Act applies to Part D beneficiaries, which limits the maximum any Medicare patient pays for covered drugs in a calendar year [6]. That cap makes Tier 3 and Tier 4 drugs more manageable than in prior years for high-cost drug users.

Patients who need step-therapy exceptions should ask their prescribing clinician to submit a letter citing the ADA 2024 Standards of Care recommendation for SGLT2 inhibitors in patients with established cardiovascular disease or high cardiovascular risk, plus EMPA-REG OUTCOME data showing a 38% reduction in cardiovascular death [2][4].

How Does the Boehringer Ingelheim and Lilly Savings Card Work for Alaska Patients?

Boehringer Ingelheim and Eli Lilly co-market Jardiance and jointly operate a commercial savings card program that can reduce eligible patients' monthly cost to as low as $10 per fill. The program applies only to commercially insured patients. Medicaid and Medicare beneficiaries are explicitly excluded by federal law.

Eligible Alaska patients can enroll online at the Jardiance website or through a prescribing clinician's office. Once enrolled, the card acts as a secondary payer at participating pharmacies. The patient pays the card's fixed copay, and the manufacturers cover the remainder of the insurer's cost-share up to a defined annual maximum.

The key limitations for Alaskan residents are pharmacy network and insurance type. The savings card does not work at pharmacies that decline third-party discount programs. Some smaller independent pharmacies in rural Alaska may not participate. Patients should confirm participation at their preferred dispensing location before counting on the savings.

For patients who are uninsured, Boehringer Ingelheim also offers a separate patient assistance program (PAP) that may provide Jardiance at no cost for income-qualifying individuals. Income thresholds and documentation requirements are set annually. A clinician or a patient advocate at a federally qualified health center (FQHC) can help complete the application. Alaska has 26 FQHC sites across the state, including facilities in Bethel, Dillingham, and Sitka, where staff are accustomed to helping patients access manufacturer assistance [7].

What Clinical Benefits Justify the Cost for Alaskan Patients?

Empagliflozin's cost becomes easier to weigh against alternatives when the clinical data are specific. The FDA has approved empagliflozin for three distinct indications, each supported by a large outcome trial [1].

For type 2 diabetes, EMPA-REG OUTCOME (N=7,020, median 3.1 years) showed a 14% reduction in the primary three-point MACE endpoint (HR 0.86; P=0.04) and a 35% reduction in hospitalization for heart failure (HR 0.65; 95% CI 0.50 to 0.85; P<0.001) [2].

For heart failure with reduced ejection fraction, EMPEROR-Reduced (N=3,730) demonstrated that empagliflozin 10 mg reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% compared with placebo (HR 0.75; 95% CI 0.65 to 0.86; P<0.001) over a median 16 months [8].

For heart failure with preserved ejection fraction, EMPEROR-Preserved (N=5,988) showed a 21% reduction in the primary endpoint (HR 0.79; 95% CI 0.69 to 0.90; P<0.001), making empagliflozin the first glucose-lowering drug proven to reduce heart failure events across the full ejection fraction spectrum [9].

For chronic kidney disease, EMPA-KIDNEY (N=6,609) found a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64 to 0.82; P<0.001), with benefits seen even in patients with an eGFR as low as 20 mL/min/1.73 m² [10].

Alaska has disproportionately high rates of type 2 diabetes in Alaska Native communities. The Alaska Native Tribal Health Consortium reports diabetes prevalence in some rural communities exceeding 20%, compared with a national average of around 11.6% [11]. Those patients carry the highest absolute cardiovascular and renal risk and thus stand to gain the most from empagliflozin's proven effects.

What Is the Cheapest Way to Get Jardiance in Alaska?

For most Alaskan patients, the lowest-cost legal path to empagliflozin depends on insurance status and clinical situation.

Commercially insured patients should activate the Boehringer Ingelheim/Lilly savings card immediately after the prescription is written. That card can drop out-of-pocket cost to $10 per month for eligible individuals, a reduction of over 98% from the cash list price.

Medicare patients should review their Part D plan's formulary during open enrollment each October through December and switch to a plan that places empagliflozin on Tier 2 or Tier 3 if their current plan places it on Tier 4 or excludes it entirely. The $2,000 Part D out-of-pocket cap effective in 2026 provides a safety net even when a plan's cost-sharing is high [6].

Uninsured patients face the steepest climb. The Boehringer Ingelheim patient assistance program can provide the drug at no cost for those who qualify by income. For those who do not qualify, a prescription from a telehealth clinician directed to a licensed 503A compounding pharmacy represents the most accessible lower-cost option. At $60 to $120 per month for compounded empagliflozin, the total annual spend drops from approximately $8,160 (branded cash price) to $720 to $1,440.

Patients should never purchase empagliflozin from international online pharmacies that do not require a valid prescription. That practice carries serious safety risks from substandard or counterfeit products and violates federal importation rules.

Can I Get a Jardiance Prescription via Telehealth in Alaska?

Telehealth prescribing of Jardiance is permitted in Alaska. Alaska was among the early states to expand telehealth practice rules, and empagliflozin is an oral medication that does not fall under any Schedule classification requiring in-person evaluation for prescribing.

A licensed clinician, including a physician, nurse practitioner, or physician assistant, may evaluate a patient via video or asynchronous telehealth, review relevant labs (fasting glucose, HbA1c, eGFR, urine albumin-to-creatinine ratio, basic metabolic panel), and issue a valid empagliflozin prescription if medically appropriate. The prescription can be sent to any Alaska retail pharmacy or, with appropriate documentation, to a licensed 503A compounding pharmacy.

HealthRX clinicians operate under this framework across Alaska, including in communities where the nearest endocrinologist may be hundreds of miles away. Patients living in remote parts of the state, from the Aleutian Islands to the North Slope, can access a clinician-reviewed empagliflozin assessment without traveling to Anchorage or Fairbanks.

Before starting empagliflozin, a clinician will typically confirm that the patient's eGFR is at or above 20 mL/min/1.73 m² (the threshold supported by EMPA-KIDNEY data), that there are no contraindications such as recurrent urinary tract infections or diabetic ketoacidosis history, and that blood pressure and volume status are appropriate [1][10].

Monitoring and Safety Considerations Specific to Alaska Patients

Rural Alaskan patients on empagliflozin face unique monitoring challenges. The drug's most common adverse effects include genital mycotic infections (occurring in approximately 6 to 10% of women and 3 to 4% of men in clinical trials) and mild polyuria from its glucosuric mechanism [1]. These effects are generally manageable but require access to follow-up care, which can be limited in communities served only by community health aides.

More serious but rare risks include diabetic ketoacidosis (DKA), particularly in patients who fast for prolonged periods, undergo surgery, or sharply reduce carbohydrate intake. The American Diabetes Association advises holding empagliflozin at least 3 to 4 days before elective surgical procedures [4]. Patients in Alaska who engage in subsistence hunting or fishing, which may involve extended periods of reduced food intake, should discuss this risk explicitly with their prescribing clinician.

Fournier's gangrene (necrotizing fasciitis of the perineum) is an extremely rare but serious SGLT2-class adverse event. The FDA added a boxed warning for this complication in 2018 [1]. Patients should be counseled to seek emergency evaluation for any signs of perineal pain, redness, or swelling.

Volume depletion is another consideration. Alaska Native patients and elderly patients on diuretics may experience hypotension or acute kidney injury if empagliflozin is started without adjusting concurrent diuretic doses. A baseline BMP and repeat testing at 4 weeks after initiation is standard practice.